Multi‐omic and comparative analyses revealed monocyte‐derived alpha‐defensin‐1 correlated with COVID‐19 severity and inhibited SARS‐CoV‐2 infection
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28845 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Xijing Qian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: COVID-19, alpha-Defensins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Shanghai Shenkang Hospital Development Center, Shanghai Rising-Star Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the etiological pathogen of coronavirus disease 2019 (COVID‐19), a highly contagious disease, spreading quickly and threatening global public health. The symptoms of COVID‐19 vary from mild reactions to severe respiratory distress or even fatal outcomes probably due to the different status of host immunity against the virus. Here in the study, we unveiled plasma proteomic signatures and transcriptional patterns of peripheral blood mononuclear cells (PBMCs) using blood samples of 10 COVID‐19 patients with different severity. Through systemic analysis, α‐defensin‐1 (DEFA1) was identified to be elevated in both plasma and PBMCs, and correlated with disease severity and stages. In vitro study demonstrated that DEFA1 was secreted from immunocytes and suppressed SARS‐CoV‐2 infection of both original and mutated strains with dose dependency. By using sequencing data, we discovered that DEFA1 was activated in monocytes through NF‐κB signaling pathway after infection, and secreted into circulation to perturb SARS‐CoV‐2 infection by interfering protein kinase C expression. It worked mainly during virus replication instead of entry in host cells. Together, the anti‐SARS‐CoV‐2 mechanism of DEFA1 has unveiled a corner of how innate immunity is against SARS‐CoV‐2 and explored its clinical potential in disease prognosis and therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai, China.
- Department of Laboratory, Zhejiang, Hangzhou, China.
- Department of Laboratory, GuangGu Branch of Hubei Maternal and Child Health Care Hospital, Wuhan, Hubei, China.
- Department of Radiology, Zhejiang, Hangzhou, China.
- Department of Radiology, GuangGu Branch of Hubei Maternal and Child Health Care Hospital, Wuhan, Hubei, China.
- Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
ORCID-Profile: Xijing Qian, Hailin Tang
Förderung
- Shanghai Shenkang Hospital Development Center
- Shanghai Rising-Star Program
- National Natural Science Foundation of China
Zitieren
APA
Qian, X., Wu, B., Chen, X., Peng, H., Liu, M., Tang, H., Xu, Z., Xu, C., & Qi, Z. (2023). Multi‐omic and comparative analyses revealed monocyte‐derived alpha‐defensin‐1 correlated with COVID‐19 severity and inhibited SARS‐CoV‐2 infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.28845
Vancouver
Qian X, Wu B, Chen X, Peng H, Liu M, Tang H, et al. Multi‐omic and comparative analyses revealed monocyte‐derived alpha‐defensin‐1 correlated with COVID‐19 severity and inhibited SARS‐CoV‐2 infection. Journal of Medical Virology. 2023. doi:10.1002/jmv.28845
BibTeX
@article{Qian2023,
author = {Qian, Xijing and Wu, Bingan and Chen, Xiang and Peng, Haoran and Liu, Miao and Tang, Hailin and Xu, Zhengmei and Xu, Chen and Qi, Zhongtian},
title = {Multi‐omic and comparative analyses revealed monocyte‐derived alpha‐defensin‐1 correlated with COVID‐19 severity and inhibited SARS‐CoV‐2 infection},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28845}
}
EUVIMED